
E-2012
CAS No. 870843-42-8
E-2012 ( E2012 )
产品货号. M16327 CAS No. 870843-42-8
一种有效的第二代 γ-分泌酶调节剂,可降低 Aβ(1-39)、Aβ(1-40) 和 A(1-42),并增加 Aβ(1-37)。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥389 | 有现货 |
![]() ![]() |
5MG | ¥648 | 有现货 |
![]() ![]() |
10MG | ¥988 | 有现货 |
![]() ![]() |
25MG | ¥1604 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称E-2012
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的第二代 γ-分泌酶调节剂,可降低 Aβ(1-39)、Aβ(1-40) 和 A(1-42),并增加 Aβ(1-37)。
-
产品描述A potent, second-generation γ-secretase modulator that decreases Aβ(1-39), Aβ(1-40) and A(1-42), and increases Aβ(1-37).Alzheimer's Disease Discontinued.
-
体外实验E2012 has concentration-dependent inhibitory effects on cholesterol biosynthesis in primary culture of rat hepatocytes and HepG2 cells with IC50s of 11.0, and 15.1 nM, respectively.
-
体内实验In vivo lenticular concentration of E 2012 after 13-week repeated dose with cataract was well above those where inhibition is observed in vitro. E 2012 induces cataract in the rat by inhibiting DHCR24 at the final step of cholesterol synthesis with associated elevation in desmosterol within the lens, preceded by desmosterol changes that would serve as a predictive safety biomarker for lenticular opacity.
-
同义词E2012
-
通路Wnt/Notch/Hedgehog
-
靶点γ-secretase
-
受体γ-secretase
-
研究领域Neurological Disease
-
适应症Alzheimer Disease
化学信息
-
CAS Number870843-42-8
-
分子量419.4912
-
分子式C25H26FN3O2
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C1N([C@H](C2=CC=C(F)C=C2)C)CCC/C1=C\C3=CC=C(N4C=C(C)N=C4)C(OC)=C3
-
化学全称2-Piperidinone, 1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-, (3E)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Portelius E, et al. J Alzheimers Dis. 2010;21(3):1005-12.
2. Borgegard T, et al. J Biol Chem. 2012 Apr 6;287(15):11810-9.
3. Borghys H, et al. J Alzheimers Dis. 2012;28(4):809-22.
产品手册




关联产品
-
BMS-708163
一种有效的、选择性的、口服生物可利用的 γ-分泌酶抑制剂,Aβ40 IC50 为 3.0 nM。
-
PF-06648671
PF-06648671 (PF6648671) 是一种新型口服γ-分泌酶调节剂,正在开发用于治疗阿尔茨海默病。
-
BMS-299897
一种有效的 γ-分泌酶抑制剂,优先抑制 APP CTF 裂解,IC50 为 7.1 nM。